JAMES MENGES: Open Payments
NPI 1427277300 · GAINESVILLE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,431 in 104 payments from 14 companies in 2025. Trend: 2023 $1,319 · 2024 $1,581 · 2025 $2,431
Food & beverage: $2,319Education: $111
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 16 | $539 |
| ABBVIE INC. | 20 | $479 |
| Teva Pharmaceuticals USA, Inc. | 10 | $258 |
| Otsuka America Pharmaceutical, Inc. | 14 | $255 |
| E.R. Squibb & Sons, L.L.C. | 10 | $170 |
| Janssen Pharmaceuticals, Inc | 7 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $151 |
| Neurocrine BioSciences, Inc. | 5 | $118 |
| Vanda Pharmaceuticals Inc. | 5 | $106 |
| Axsome Therapeutics, Inc. | 4 | $92 |
Products named: VRAYLAR, ARISTADA, ABILIFY ASIMTUFII, INVEGA SUSTENNA, COBENFY, CAPLYTA, INGREZZA, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
